Oncolytic Viruses.pdf

Oncolytic viruses are being researched as a potential treatment for various types of cancer, including head and neck tumors. These viruses selectively infect and kill cancer cells, while sparing healthy cells. The mechanism of action involves infecting tumor cells with a virus that replicates inside them, causing cell lysis and releasing new virions. This approach has shown promise in preclinical studies, with high effectiveness and low side effects.

Key benefits of oncolytic virus therapy include:

Ability to target specific cancer cells, reducing harm to healthy cells
Potential to be used in combination with standard cancer treatments, such as chemotherapy and radiotherapy
Low systemic toxicity and minimal side effects
Ability to stimulate an immune response against cancer cells

Challenges in developing oncolytic virus therapy include:

Finding effective methods for administering the viruses to tumors
Overcoming the immune system's response to the virus, which can limit its effectiveness
Determining the optimal dose of virus required for therapeutic effect without causing adverse reactions

Research has focused on modifying the genetic material of viruses to increase their specificity for cancer cells and reduce their toxicity. This can be achieved by:

Modifying the viral receptor to target specific molecules on cancer cells
* Removing viral genes responsible for initiating replication in healthy cells

Head and neck cancers, which account for approximately 5.3% of all malignancies in Poland, are a potential target for oncolytic virus therapy. These cancers are often aggressive and have limited treatment options, making oncolytic virus therapy a promising area of research.